Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by SPCEO1on Mar 21, 2023 8:08am
356 Views
Post# 35350646

Looks like IM phase III test has been successful

Looks like IM phase III test has been successful
Zhongyu Trogarzo intramuscular injection phase III data is expected to be released in April
Response(0) Popularity( 74 ) Favorite(0)2023/03/21 10:44
MoneyDJ News 2023-03-21 10:44:18 Reported by reporter Xiao Yanxiang
 
Zhongyu (4147), a new drug research and development company, used Trogarzo intramuscular injection for the post-AIDS treatment. Phase III clinical trials have been completed. According to market estimates, the data is expected to be released in April. The new core product TMB365/380, which has attracted more attention from the outside world, has completed the three-dose safety test of the Pioneer Group, and the data will be released in late June at the earliest.
 
In addition to the initial intravenous injection dosage form, Zhongyu's existing drug Trogarzo has gradually added intravenous injection and intramuscular injection dosage forms. Among them, the intravenous injection dosage form has obtained the US drug certification last year and is expected to be launched in the second quarter of this year. In addition, the phase III clinical trial of the intramuscular injection dosage form is in the final data collection stage, and the successful data will be released in April, and the application for drug certificate will be submitted in the second quarter, and the certificate will be obtained in the first quarter of next year.
 
In addition, TMB356/380, which is used for the long-term maintenance therapy of first-line AIDS patients, is currently in Phase 1b/2 stage. The three groups of pioneer groups mainly test the safety of three doses. At present, the cases of the three groups have been accepted and entered the three-month medication stage . The data is expected to be released in late June at the earliest.
<< Previous
Bullboard Posts
Next >>